financetom
Business
financetom
/
Business
/
Klaviyo Q3 revenue up 32%, beats estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Klaviyo Q3 revenue up 32%, beats estimates
Nov 5, 2025 2:26 PM

Overview

* Klaviyo ( KVYO ) Q3 revenue grows 32% yr/yr to $310.9 mln, beating analyst expectations

* Company raises FY25 revenue guidance to $1.215 bln-$1.219 bln, indicating 30% growth

* Klaviyo ( KVYO ) reports net loss for Q3 despite strong revenue growth

Outlook

* Klaviyo ( KVYO ) raises FY25 revenue guidance to $1.215 bln to $1.219 bln

* Company expects Q4 revenue between $331 mln and $335 mln

* Company projects Q4 non-GAAP operating margin of 13% to 14%

Result Drivers

* LARGE CUSTOMER GROWTH - Klaviyo ( KVYO ) saw a 36% increase in customers generating over $50,000 in ARR, indicating strong growth among larger clients

* INTERNATIONAL EXPANSION - Revenue in EMEA and APAC grew 43% year-over-year, driven by international expansion

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $310.90 $299.86

Revenue mln mln (21

Analysts

)

Q3 Net -$426,00

Income 0

Q3 $237.10

Adjusted mln

Gross

Profit

Q3 $45 mln

Adjusted

Operatin

g Profit

Q3 Gross $234.70

Profit mln

Q3 -$614,00

Pretax 0

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 22 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the software peer group is "buy"

* Wall Street's median 12-month price target for Klaviyo Inc ( KVYO ) is $45.00, about 42.2% above its November 4 closing price of $26.00

* The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 48 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US to build new stockpile of bird flu vaccine for poultry
US to build new stockpile of bird flu vaccine for poultry
Jan 8, 2025
* USDA says new vaccines will match current virus strain * Current outbreak has killed over 130 million birds in all 50 states * Trade risks hinder immediate vaccine deployment, Agriculture Secretary Vilsack has said (Adds impact on egg prices, paragraph 2, background, quotes on prior vaccine development in paragraphs 8-12) By Leah Douglas and Tom Polansek Jan 8 (Reuters)...
Accolade to be Acquired, Taken Private by Transcarent in $621 Million Deal
Accolade to be Acquired, Taken Private by Transcarent in $621 Million Deal
Jan 8, 2025
02:43 PM EST, 01/08/2025 (MT Newswires) -- Accolade (ACCD) agreed to be acquired and delisted by Transcarent in a $621 million deal that's expected to deliver a more personalized healthcare experience for people. Transcarent, which recently launched a WayFinding artificial intelligence chatbot that promises instant and trusted health information, will pay $7.03 per Accolade share, according to a joint statement...
Update: Shell Shares Fall After Projecting Weaker Q4 LNG Production due to Trading Challenges
Update: Shell Shares Fall After Projecting Weaker Q4 LNG Production due to Trading Challenges
Jan 8, 2025
02:19 PM EST, 01/08/2025 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph.) Shell's (SHEL) US-listed shares were down 2% in recent trading Wednesday after saying it expects weaker Q4 oil and gas trading results, compared with the prior quarter due to lower liquefied natural gas, or LNG, production and lower trading performance. LNG liquefaction...
J&J pauses rollout of heart device in the US to investigate stroke risk
J&J pauses rollout of heart device in the US to investigate stroke risk
Jan 8, 2025
Jan 8 (Reuters) - Johnson & Johnson ( JNJ ) said on Wednesday that it has temporarily paused the rollout of its Varipulse heart device in the United States, citing an abundance of caution as the company investigates four reported stroke events. The Varipulse, a pulsed field ablation system, received U.S. Food and Drug Administration approval in November for treating...
Copyright 2023-2026 - www.financetom.com All Rights Reserved